MODIFICATION
A -- Elemental Analysis for Biological Samples - Amendment 1
- Notice Date
- 8/25/2010
- Notice Type
- Modification/Amendment
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-SOL-1076171
- Archive Date
- 9/15/2010
- Point of Contact
- Natalie Mitchell, Phone: 3018279606, Gina Jackson, Phone: 301-827-1982
- E-Mail Address
-
natalie.mitchell@fda.hhs.gov, gina.jackson@fda.hhs.gov
(natalie.mitchell@fda.hhs.gov, gina.jackson@fda.hhs.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- Evaluation factors - Technical capability was updated to take out 'flow cytometer'. Questions and Answers Question 1 From the FDA website it looks like Au, Cd, Mg, Si, Ti, and Ag are of interest? Can you provide any further details? Si and Mg are short-lived and would need to be run under a different prep if done by NAA. Also, the max vial size for these would be 7cc. For Cd, Ti, and Ag, a 1ug detection limit is predicted if run under similar irradiation conditions as last time. Answer Further details on elements of interest: The elements listed are the ones most likely to be analyzed this coming fiscal year. Of that list, the majority of the samples will almost certainly be Au, followed by Si. It is anticipated that only 1 element will need to be analyzed per sample (i.e. either Au OR Si, not both Au and Si). The majority of the samples will be biologically-based (i.e. tissues, blood, etc). Analysis of Si and Mg: The solicitation allows for either NAA or ICPMS to be used (you are not limited to only one method), so if ICPMS will allow for better sensitivity for these samples, or can handle larger volumes, then please have your bid reflect this. For Si, if 7cc is the maximum volume that either method can handle, please include in the sample preparation line item the cost for sample homogenization. Question 2 Part 2 section B identifies that the samples may be analyzed by either ICP-MS or INAA. Section 2 part H mandates that the contracting laboratory must have both ICP-MS AND INAA capabilities. Since it is prohibitively expensive to attain an INAA system private companies subcontract to universities. Since the INAA analysis must be subcontracted does this negate the feasibility of small businesses to respond to the solicitation since none of them will have the capability in-house? Answer: It is ok to subcontract as long as the small business maintains 51% of the actual work. Question 3 Part 8 section "Technical Acceptability" requires the contract laboratory to "Provide experience within the last 3 years of providing this type of service for the same brand flow cytometer." The application of a flow cytometer is not mentioned previously in the scope of work. Is this a typo? Answer: Yes, Flow cytometer was a typo
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-SOL-1076171/listing.html)
- Place of Performance
- Address: FDA/CDER, Building 64, Room 2086, 10903 New Hampshire Ave, Silver Spring, Maryland, 20903, United States
- Zip Code: 20903
- Zip Code: 20903
- Record
- SN02254512-W 20100827/100825235451-2239d8953e317595951d6a91eca94414 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |